Last reviewed · How we verify
MMR-V
At a glance
| Generic name | MMR-V |
|---|---|
| Also known as | ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine) |
| Sponsor | Novartis Vaccines |
| Modality | Biologic |
| Phase | Phase 3 |
Approved indications
Common side effects
- Irritability
- Pain
- Redness
- Drowsiness
- Loss of appetite
- Administration site pain
- Pyrexia
- Fever
- Swelling
- Administration site erythema
- Upper respiratory tract infection
- Otitis media
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age (PHASE2)
- Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. (PHASE2)
- A Retrospective Validations Microsatellite Instability (MSI) Testing v Mismatch Repair (MMR) in Gastric Adenocarcinoma
- Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene (PHASE1, PHASE2)
- Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children (PHASE3)
- A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMR-V CI brief — competitive landscape report
- MMR-V updates RSS · CI watch RSS
- Novartis Vaccines portfolio CI